Wall Street brokerages forecast that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will report ($0.15) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Achillion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.16). Achillion Pharmaceuticals posted earnings of ($0.03) per share in the same quarter last year, which would suggest a negative year over year growth rate of 400%. The company is scheduled to report its next quarterly earnings results on Thursday, February 22nd.
On average, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.63) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.60). For the next financial year, analysts forecast that the firm will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.79) to ($0.55). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same period last year, the firm earned ($0.15) earnings per share.
In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the business’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total transaction of $50,510,201.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 7.24% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in shares of Achillion Pharmaceuticals by 51.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock valued at $2,581,000 after buying an additional 207,204 shares during the last quarter. Deschutes Portfolio Strategy LLC grew its position in shares of Achillion Pharmaceuticals by 358.6% in the 2nd quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock valued at $535,000 after buying an additional 91,200 shares during the last quarter. Senzar Asset Management LLC bought a new stake in shares of Achillion Pharmaceuticals in the 2nd quarter valued at about $4,966,000. Candriam Luxembourg S.C.A. bought a new stake in shares of Achillion Pharmaceuticals in the 3rd quarter valued at about $1,976,000. Finally, Bank of New York Mellon Corp grew its position in shares of Achillion Pharmaceuticals by 11.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 611,634 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 62,515 shares during the last quarter. Institutional investors and hedge funds own 76.98% of the company’s stock.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) traded down $0.10 during midday trading on Friday, reaching $3.02. The company’s stock had a trading volume of 3,914,093 shares, compared to its average volume of 2,396,773. Achillion Pharmaceuticals has a 52-week low of $2.92 and a 52-week high of $5.66.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.